Close Menu

NEW YORK – Oncocyte said Thursday that it has entered a distribution agreement with CORE Diagnostics to expand the commercial availability of its DetermaRx test to India, the Middle East, and Africa.

DetermaRx is Oncocyte’s first commercially launched assay and was initially called the Razor Genomic test when Oncocyte acquired Razor and it's IP last year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.